Aarti Pharmalabs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aarti Pharmalabs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹48 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹36 tied up three years earlier. More money tied up than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹122Over the last 3 years, every ₹100 of reported profit came with ₹122 of operating cash.
Higher than 57% of Healthcare companies in India.
Self-Funding Ratio
0.7×Over the last 3 years its own operating cash paid for 74% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 74% of Healthcare companies in India.
Cash Locked Ratio
₹48For every ₹100 of sales, ₹48 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹36 tied up three years earlier.
More money tied up than 88% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 8%
Sales fell 8% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-8% / +55%In 3 years sales changed by -8% while total assets changed by +55%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.5×Debt due within a year is covered 0.5 times by its yearly operating cash.
Lower than 70% of Healthcare companies in India.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in India.
Tangible Assets Ratio
96%Of every ₹100 the company owns, ₹96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 54% of Healthcare companies in India.
Tangible Net Worth Ratio
94%Of every ₹100 of net worth, ₹94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 54% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Aarti Pharmalabs Limited owes ₹0.39 for every ₹1 it owns. Net profit fell 36% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
35.3Investors pay ₹35.3 for every ₹1 of Aarti Pharmalabs Limited's yearly profit, lower than 54% of Healthcare companies in India.
P/B ratio
3.54The share price is 3.54 times Aarti Pharmalabs Limited's book value per share, lower than 65% of Healthcare companies in India.
Market cap
₹7,516 CrThe total market value of all of Aarti Pharmalabs Limited's shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹2,125 CrWhat Aarti Pharmalabs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹234.30Net worth divided by the number of shares. The share price of ₹828.80 is 3.5 times this, which is the P/B above.
Return on equity (ROE)
10.0%Aarti Pharmalabs Limited earned 10.0% on its shareholders' money over the last year, lower than 67% of Healthcare companies in India.
Owes vs Owns
0.39×Aarti Pharmalabs Limited owes ₹0.39 for every ₹1 it owns (low), higher than 56% of Healthcare companies in India.
Dividend yield
0.47%Aarti Pharmalabs Limited pays 0.47% of its share price as dividends a year, higher than 60% of dividend-paying Healthcare companies in India.
Revenue growth
-14%Revenue fell 14% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Profit growth
-36%Net profit fell 36% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Profit margin
9.8%Aarti Pharmalabs Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
1.5×Cash from Aarti Pharmalabs Limited's business was 1.5× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
6.4×Aarti Pharmalabs Limited's operating profit covered its interest costs 6.4 times in the year to Mar 2026.
Cash vs debt
Net debtAarti Pharmalabs Limited had ₹760 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Aarti Pharmalabs Limited's P/E ratio?
Investors pay ₹35.3 for every ₹1 of Aarti Pharmalabs Limited's yearly profit, lower than 54% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aarti Pharmalabs Limited: ₹7,516 Cr ÷ ₹2,125 Cr (31 Mar 2026) = 3.5.
What is Aarti Pharmalabs Limited's return on equity?
Aarti Pharmalabs Limited earned 10.0% on its shareholders' money over the last year, lower than 67% of Healthcare companies in India.
How much does Aarti Pharmalabs Limited owe compared with what it owns?
Aarti Pharmalabs Limited owes ₹0.39 for every ₹1 it owns (low), higher than 56% of Healthcare companies in India.
Does Aarti Pharmalabs Limited pay a dividend?
Yes. Aarti Pharmalabs Limited pays 0.47% of its share price as dividends a year, higher than 60% of dividend-paying Healthcare companies in India.
Is Aarti Pharmalabs Limited's revenue growing?
Revenue fell 14% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.